|Publication type:||Article in scientific journal|
|Type of review:||Peer review (publication)|
|Title:||Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation|
Passweg, Jakob R.
Halter, Jörg P.
Buser, Andreas S.
|Published in:||Transfusion and Apheresis Science|
|Publisher / Ed. Institution:||Elsevier|
|Subjects:||HLA antibody; HPA antibody; Hematopoietic cell transplantation; Matched related; Donor derived|
|Subject (DDC):||617: Surgery|
|Abstract:||Background and objectives: Antibodies (Ab) against HLA and HPA antigens play an important role in HCT. In this prospective study we evaluated prevalence and kinetics of HLA- and HPA-Ab after HCT, including a possible donor-recipient transfer and their clinical relevance in respect to platelet transfusion refractoriness (PTR). Materials and methods: Patients were consecutively recruited. Ab were determined by microbead assay technique and a mean fluorescence intensity cut-off of 1,000. Results: At baseline, 21 donors (42%) and 27 patients (54%) had HLA-Ab with a mean panel reactivity (cPRA) of 34.9 ± 29.4% and 46.1 ± 36.5%, respectively. We observed a significant higher number of HLA-Ab specificities in female donors and patients and a predominance of HLA-class I Ab. At day 0 we detected an increase of HLA-Ab (from 526 to 673) and cPRA (55.2 ± 31.9%). Thirty-six patients (72%) developed new HLA-Ab, mainly 3 weeks after HCT. In 7 patients an HLA-Ab with the same specificity as detected in the corresponding donor emerged, suggesting a possible transfer from the donor to the recipient. Overall, MFI showed a high variation. Type and number of transfusions were not associated with number and intensity of HLA-Ab (ρ: -0.05 – 0.02). Number of HLA-Ab, cPRA and intensity were not associated with PTR, which occurred in 9 patients (18%) and none had bleeding WHO > 2. Conclusions: Although a considerable number of patients have and develop HLA-Ab before and early after HCT, we found no association with PTR and bleeding and management should be individualized.|
|Fulltext version:||Published version|
|License (according to publishing contract):||Licence according to publishing contract|
|Departement:||School of Health Sciences|
|Organisational Unit:||Institute of Public Health (IPH)|
|Appears in collections:||Publikationen Gesundheit|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.